Abstract: The application provides methods of treating a subject suffering from advanced-stage GvHD with ?1-antitrypsin (AAT), any carboxy terminal peptide derivatives thereof, or any recombinant versions thereof. In certain embodiments, the subject is a glucocorticoid-refractory patient having GvHD with gut involvement. In other embodiments, donor subjects of a transplant are treated with AAT, any carboxy terminal peptide derivatives thereof, or any recombinant versions thereof, to reduce graft rejection or GvHD in a recipient subject.

Abstract: Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure.

Abstract: Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure.

Abstract: Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure.

Abstract: Embodiments described herein relate to compositions, methods and uses for alpha-1 antitrypsin (AAT) or derivatives or analogs or peptides or mutants thereof for treating a subject exposed to radiation. In certain embodiments, AAT or derivatives thereof or analogs thereof can be used to modulate adverse effects of radiation therapy on subjects undergoing treatment for cancer. In other embodiments, compositions disclosed herein can be used for treating a subject having been exposed to non-therapeutic or accidental radiation. Some embodiments reported herein concern compositions and methods for enhancing radiotherapy. Certain embodiments relate to methods and compositions for preventing or reducing radiation exposure-induced cellular damage in a subject.

Abstract: Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure.

Abstract: The immunogenicity of transfused or transplanted, allogeneic tissue is reduced by either directly exposing the tissue to ultraviolet (UV) irradiation prior to administering the tissue to the recipient or by inducing a state of tolerance in the recipient to non-UV or UV-irradiated allogeneic tissue by prior exposure to UV-irradiated allogeneic tissue.